Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency

[1]  Jay L. Martello,et al.  Ecallantide for treatment of acute attacks of hereditary angioedema. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[2]  M. Triggiani,et al.  Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group , 2012, Allergy.

[3]  P. Busse,et al.  Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  B. Chipps.  Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema , 2011, Pediatrics.

[5]  W. Lumry,et al.  Safety and Efficacy of Nanofiltered C1 Esterase Inhibitor (Human) (Cinryze™) for the Treatment of Laryngeal Attacks in Subjects with Hereditary Angioedema (HAE) , 2011 .

[6]  W. Lumry,et al.  Pre-procedure Administration of C1 Esterase Inhibitor (Human) (Cinryze™) for the Prevention of Hereditary Angioedema (HAE) Attacks after Medical, Dental, or Surgical Procedures , 2011 .

[7]  W. Lumry,et al.  Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies , 2011, The World Allergy Organization journal.

[8]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[9]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[10]  A. Kaplan,et al.  The plasma bradykinin-forming pathways and its interrelationships with complement. , 2010, Molecular immunology.

[11]  T. Bowen.  Hereditary Angioedema Consensus 2010 , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[12]  H. Farkas.  Management of upper airway edema caused by hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[13]  P. Keith,et al.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[14]  M. Gompels,et al.  HAE international home therapy consensus document , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[15]  K. Bork.  Recurrent angioedema and the threat of asphyxiation. , 2010, Deutsches Arzteblatt international.

[16]  T. Craig,et al.  Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2) , 2010, Expert review of clinical immunology.

[17]  M. Smythe,et al.  Unfractionated Heparin Dosing for Venous Thromboembolism in Morbidly Obese Patients: Case Report and Review of the Literature , 2010, Pharmacotherapy.

[18]  J. Bernstein,et al.  Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.

[19]  T. Craig,et al.  When is prophylaxis for hereditary angioedema necessary? , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  M. Cicardi,et al.  C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. , 2009, Trends in molecular medicine.

[21]  H. Farkas,et al.  Disease expression in women with hereditary angioedema. , 2008, American journal of obstetrics and gynecology.

[22]  K. Bork,et al.  Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[23]  G. Kojda,et al.  Nonallergic angioedema: role of bradykinin , 2007, Allergy.

[24]  M. Frank.  Hereditary angioedema: the clinical syndrome and its management in the United States. , 2006, Immunology and allergy clinics of North America.

[25]  L. Romics,et al.  Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.

[26]  M. Gompels,et al.  C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.

[27]  A. Tordai,et al.  HAEdb: A novel interactive, locus‐specific mutation database for the C1 inhibitor gene , 2005, Human mutation.

[28]  A. Tordai,et al.  Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.

[29]  W. Tremaine,et al.  Hereditary angioedema: a broad review for clinicians. , 2001, Archives of internal medicine.

[30]  H. Farkas,et al.  Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema , 2001, European journal of gastroenterology & hepatology.

[31]  H. Farkas,et al.  The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. , 1999, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[32]  K. Bork,et al.  Hepatocellular adenomas in patients taking danazol for here ditary angiooedema , 1999, The Lancet.

[33]  M. Tosi.  Molecular genetics of C1 inhibitor. , 1998, Immunobiology.

[34]  M. Cicardi,et al.  Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. , 1997, The Journal of allergy and clinical immunology.

[35]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[36]  F. Rosen,et al.  Hereditary Angioneurotic Edema: Two Genetic Variants , 1965, Science.

[37]  R. R. Evans,et al.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. , 1963, The American journal of medicine.